retatrutide phase 2 trial obesity nejm 2023 🤔 Adults with type diabetes (T2D) and lose less weight on EVERY GLP-1 drug compared to those without diabetes, consistently ~5% less. Now that we have retatrutide's TRIUMPH-2 data today Medscape | The investigational triple

Afkarian M, Sachs MC, Kestenbaum B, et al

Testosterone effects are not yet apparent as blood levels are still building

GLP-1 medications like semaglutide work by building up in your system over weeks, so a single gap in your weekly routine is manageable if you respond correctly within 24 to 48 hours

Research Context Retatrutide was initially developed as a therapeutic candidate for type 2 diabetes and obesity due to its ability to modulate multiple gastrointestinal and endocrine pathways

Sites to Avoid and When to Seek Medical Advice Avoid injecting into broken, infected, or scarred skin, areas of lipohypertrophy, or within 5 cm of the navel

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses